<DOC>
	<DOCNO>NCT01491295</DOCNO>
	<brief_summary>1 . Adefovir add-on therapy superior switch adefovir monotherapy entecavir 1mg monotherapy chronic hepatitis B ( CHB ) patient lamivudine resistance ( LAM-R ) 2 . Long-term adefovir add-on therapy effective viral suppression . However , economic burden dual antiviral therapy heavy infinite treatment . 3 . Tenofovir disoproxil fumarate ( TDF ) potent antiviral agent . TDF demonstrate potent antiviral efficacy subset lamivudine experience HBeAg-positive patient . TDF also superior ADV HBeAg-negative HBeAg-positive treatment-naive patient . 4 . Theoretically , TDF replace LAM/ADV viral suppression achieve LAM/ADV combination treatment LAM-R CHB patient .</brief_summary>
	<brief_title>Switch Tenofovir Versus Continue Lamivudine/Adefovir Treatment Lamivudine-resistance Chronic Hepatitis B Patients</brief_title>
	<detailed_description>Hepatitis B virus ( HBV ) partially double-stranded DNA virus . HBV infection induce spectrum disease range asymptomatic infection severe chronic liver disease , include cirrhosis hepatocellular carcinoma ( HCC ) . Chronic HBV infection also major cause HCC Taiwan . Over 350 million people worldwide chronically infect HBV . Lamivudine first marketing first-line oral anti-viral agent therapy chronic hepatitis B. Infinite nucleoside analogue therapy may need long-term viral suppression especially patient HBeAg-negative chronic hepatitis B . The initial randomized study demonstrate clinical benefit safety lamivudine hepatitis B e antigen ( HBeAg ) -positive -negative chronic hepatitis B patient . But high 20 % case 1-year lamivudine treatment develop genotypic resistance , define presence YMDD mutation HBV polymerase region . Genotypic resistance almost always associate virological breakthrough exacerbation liver function . Long-term lamivudine therapy report increase HBeAg seroconversion provide clinical improvement ALT level . However , four-year follow-up study , YMDD-variant HBV detect high 67 % patient lamivudine treatment . Several clinical study prove adefovir add-on therapy superior switch adefovir monotherapy entecavir 1mg monotherapy chronic hepatitis B ( CHB ) patient lamivudine resistance ( LAM-R ) . Currently , AASLD EASL guideline recommend adefovir add-on therapy standard treatment LAM-R CHB patient . Long-term adefovir add-on therapy effective viral suppression ( 8 ) . However , economic burden dual antiviral therapy heavy infinite treatment . Tenofovir disoproxil fumarate ( TDF ) potent antiviral agent . TDF ETV recommend oral first-line therapy CHB . TDF demonstrate potent antiviral efficacy subset lamivudine experience HBeAg-positive patient . TDF also superior ADV HBeAg-negative HBeAg-positive treatment-naive patient . Theoretically , TDF replace LAM/ADV viral suppression achieve LAM/ADV combination treatment LAM-R CHB patient . This clinical trial proof concept study evaluate efficacy switch TDF monotherapy patient .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>HBsAgpositive 6 month ( HBeAgpositive HBeAgnegative ) . Age &gt; 20 y/o . Under lamivudine/adefovir treatment 1 year due previous lamivudine resistance ( LAMR ) , current HBV DNA undetectable ( &lt; 20 IU/ml ) enrollment . HCV , HIV , HDV coinfection . Uncontrolled HCC , malignancy decompensated liver cirrhosis ( CTP score ≥ 7 ) . Uremia patient Creatinine ≥ 2 mg/dl .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Lamivudine</keyword>
	<keyword>adefovir add treatment</keyword>
	<keyword>tenofovir</keyword>
	<keyword>chronic hepatitis B</keyword>
</DOC>